Slingshot Insights | Jnj Overview

JNJ Overview

Upcoming Projects (JNJ)

Don’t see a project related to the company you care about? Create your own!

Executed Projects (JNJ)

Quarterly Survey: Knee and Hip Replacement Brand Usage and Preferences April 2023
Tickers: JNJ, SYK, ZBH, SNN, MDT
Executed On: Apr 14, 2023 at 03:38 PM EDT
Quarterly Survey: Breast Implants April 2023
Tickers: AGN, JNJ, SIEN
Executed On: Apr 14, 2023 at 03:38 PM EDT
Quarterly Survey: Knee and Hip Replacement Brand Usage and Preferences March 2023
Tickers: ZBH, SYK, JNJ, SNN, MDT
Executed On: Mar 14, 2023 at 04:03 PM EDT
Quarterly Survey: Breast Implants February 2023
Tickers: AGN, JNJ, SIEN
Executed On: Feb 07, 2023 at 06:12 PM EST
A Second View: Examining Addex Therapeutics' ADX71149/JNJ-40411813 in combination with Levetiracetam or Brivaracetam in patients with Epilepsy
Tickers: ADXN, JNJ
Executed On: Feb 03, 2023 at 04:00 PM EST
Examining Addex Therapeutics' ADX71149/JNJ-40411813 in combination with Levetiracetam or Brivaracetam in patients with Epilepsy
Tickers: ADXN, JNJ
Executed On: Feb 02, 2023 at 03:50 PM EST
Discussing the potential of PARP-inhibitor, Lynparza (olaparib), in combination with abiraterone for patients with mCRPC
Tickers: AZN, JNJ, SUNPHARMA.XBOM
Executed On: Nov 01, 2022 at 11:00 AM EDT
A look at the use of ELIQUIS, Xarelto, and other blood thinners for cardiovascular disease and atrial fibrillation
Tickers: BMY, JNJ
Executed On: Aug 25, 2022 at 02:00 PM EDT
A Second View: Discussing BCMA targeted therapies in r/r multiple myeloma
Tickers: JNJ, GSK, BMY, TSVT, LEGN
Executed On: Jan 06, 2022 at 03:00 PM EST

Expired Projects (JNJ)

Analyzing Legend Biotech’s ciltacabtagene autoleucel, BCMA-directed chimeric antigen receptor T cell (CAR-T) therapy for the treatment of multiple myeloma, ahead of extended PDUFA February 28, 2022
Tickers: LEGN, JNJ, BMY
Execute By: Feb 28, 2022

Upcoming & Overdue Catalysts (JNJ)

Don’t see a catalyst related to the company you care about? Create your own!

Occurred Catalysts (JNJ)

Nine-Month Data Released from MeiraGTx (MGTX) and J&J (JNJ) Phase 1/2 Trial of AAV-RPGR in X-Linked Retinitis Pigmentosa (XLRP)
Tickers: MGTX, JNJ
Occurred on: Oct 03, 2020
Johnson & Johnson (JNJ) Announces that Janssen’s COVID-19 Investigational Vaccine Candidate Prevents Severe Clinical Disease in Pre-clinical Studies
Ticker: JNJ
Occurred on: Sep 03, 2020
EU in talks with Moderna, BioNtech, Sanofi, Johnson & Johnson and CureVac to secure possible COVID vaccines
Tickers: JNJ, SNY, BNTX, MRNA
Occurred on: Jul 17, 2020
Aduro Biotech (ADRO) expected to initiate Phase 1b/2 trial of ADU-214/JNJ-64041757 in lung cancer in 2017 (Partnership with Janssen)
Tickers: ADRO, JNJ
Occurred on: Jun 07, 2018
Johnson & Johnson (JNJ) expects to launch Phase III data on esketamine, an antidepressant, by late 2017
Ticker: JNJ
Occurred on: Apr 18, 2018
3½-Year Follow-Up Data of IMBRUVICA (ibrutinib) in Patients with Relapsed/Refractory Mantle Cell Lymphoma
Ticker: JNJ
Occurred on: Dec 09, 2017
New Analysis of Janssen's (JNJ) INVOKANA (canagliflozin) in reduction of Cardiovascular (CV) Risk Reductions in Type 2 Diabetes Patients With and Without a History of Prior CV Events Released
Ticker: JNJ
Occurred on: Nov 14, 2017
Janssen's(JNJ) XARELTO (rivaroxaban) 10 mg Dose in Reducing the Risk of Recurrent Venous Thromboembolism (VTE) PDUFA expected October 28, 2017
Ticker: JNJ
Occurred on: Oct 30, 2017
XARELTO (rivaroxaban) Significantly Reduced Major Cardiovascular Events in Patients with Stable Coronary and Peripheral Artery Disease in Pivotal Phase 3 Study
Ticker: JNJ
Occurred on: Aug 27, 2017
Johnson & Johnson (JNJ) to report first quarter earnings results in Investor Conference Call on April 18th, 2017
Ticker: JNJ
Occurred on: Apr 18, 2017
Johnson & Johnson (JNJ) subsidiary Janssen releases Phase 3 study on Xarleto versus aspirin in treating recurrent blood clots without increase in bleeding in Venous Thromboembolism patients
Ticker: JNJ
Occurred on: Mar 18, 2017
Johnson & Johnson (JNJ) Phase 2 study shows data of Guselkumab versus Humira in treating moderate to severe plaque psoriasis
Ticker: JNJ
Occurred on: Mar 03, 2017
European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) Recommends Expanded Use of Janssen's (JNJ) Darzalex + Celgene's (CELG) Revlimid and Takeda's (TKPYY) Velcade for Multiple Myeloma
Tickers: JNJ, CHMP, TKPYY
Occurred on: Feb 24, 2017
Johnson & Johnson (JNJ) launches new data of Stelara treating adults with moderate to severe active Crohn's disease
Ticker: JNJ
Occurred on: Feb 17, 2017
Achillion (ACHN) and Janssen (JNJ) Announce Start of Enrollment for Phase 2b OMEGA-1 Trial Evaluating JNJ-4178 (Odalasvir/Simeprevir/AL-335) in Patients with Treatment-Naive Chronic Hepatitis C Virus Infection (HCV) Without Cirrhosis
Tickers: ACHN, JNJ
Occurred on: Dec 28, 2016
Johnson & Johnson (JNJ) subsidiary Janssen submits pair of FDA applications for Simponi Aria in treating active psoriatic arthritis and active ankylosing spondylitis
Ticker: JNJ
Occurred on: Dec 21, 2016
Janssen (JNJ) Submits Marketing Application in Japan for Darzalex in Multiple Myeloma
Tickers: JNJ, GNMSF
Occurred on: Dec 20, 2016
Viiv Healthcare Presents Results from 2 Phase 3 Studies Evaluating Dolutegravir + Rilpivirine in HIV Maintenance
Tickers: VIIV HEALTHCARE, PFE, JNJ, GSK, SGIOF
Occurred on: Dec 20, 2016
Janssen, Johnson & Johnson (JNJ) subsidiary submits FDA approval for Stelara in treating adolescents with moderate to severe plaque psoriasis
Ticker: JNJ
Occurred on: Dec 15, 2016
Janssen (JNJ) Initiates Phase 2b Study Evaluating Simeprevir/Odalasvir/JNJ-4178 in Chronic Hepatitis C Virus Infection Genotypes 1,2,4,5 and 6 Without Cirrhosis
Tickers: JNJ, GILD, ABBV
Occurred on: Nov 28, 2016
Johnson & Johnson (JNJ) subsidiary Janssen files EMA application for approval of Guselkumab in treating moderate to severe plaque psoriasis
Ticker: JNJ
Occurred on: Nov 25, 2016
JNJ subsidiary Janssen files FDA application for approval of Guselkumab for treating moderate to severe plaque psoriasis
Ticker: JNJ
Occurred on: Nov 25, 2016
PDUFA Date of February 17, 2017 for Janssen's (JNJ) Daratumumab in Relapsed Multiple Myeloma
Ticker: JNJ
Occurred on: Nov 21, 2016
Janssen (JNJ) Submits Biologics License Application (BLA) to the FDA for Guselkumab in Treatment of Adults with Moderate-to-Severe Plaque Psoriasis
Ticker: JNJ
Occurred on: Nov 17, 2016
Janssen's (JNJ) Stelara Approved by European Commission for Adults with Moderately to Severely Active Crohn's Disease
Tickers: JNJ, Janssen Biotech
Occurred on: Nov 11, 2016
Merrimack Pharma's (TEVA) Abbreviated New Drug Application (ANDA) for Generic Version of Janssen's (JNJ) Doxorubicin Accepted for Review by FDA
Tickers: TEVA, JNJ, Merrimack Pharmaceuticals
Occurred on: Oct 31, 2016
Regeneron (REGN) and Sanofi's (SNY) Sarilumab for Rheumatoid Arthritis Granted PDUFA date of October 30, 2016 by FDA
Tickers: REGN, JNJ, SNY, GSK
Occurred on: Oct 28, 2016
FDA Concludes that Johnson & Johnson's (JNJ) Blood Thinner XARELTO is Safer Than Bristol-Myers Squibb's (BMY) Warfarin in Patients with Atrial Fibrillation
Tickers: BMY, JNJ, ALR
Occurred on: Oct 11, 2016
PDUFA for Stelara (ustekinumab) Adult patients with moderate-to-severe Crohn's set for Sept 2016
Ticker: JNJ
Occurred on: Sep 26, 2016
GlaxoSmithKline (GSK) and Johnson & Johnson (JNJ) Plan to Submit Application to FDA in 2016 for Sirukumab in Rheumatoid Arthritis
Tickers: GSK, REGN, SNY, JNJ
Occurred on: Sep 23, 2016
Achillion Announces 100% SVR12 in the 6-Week and 8-Week Cohorts in Janssen's Phase 2 Trial Evaluating the Triple Combination Treatment Regimen Including Odalasvir, AL-335, and Simeprevir for Genotype 1 Treatment-Naïve HCVv
Tickers: ACHN, JNJ
Occurred on: Sep 23, 2016
FDA Approves Janssen's (JNJ) INVOKAMET XR in Treatment of Adults with Type 2 Diabetes
Ticker: JNJ
Occurred on: Sep 21, 2016
Janssen's (JNJ) Stelara Recommended for Approval by European Ad Comm for Treatment of Crohn's Disease
Ticker: JNJ
Occurred on: Sep 16, 2016
Johnson & Johnson (JNJ) Announces $4.325B Cash Deal to Acquire Abbott's (ABT) Medical Optics Business
Tickers: JNJ, ABT
Occurred on: Sep 16, 2016
GlaxoSmithKline (GSK) and Johnson & Johnson (JNJ) Submit Sirukumab in Treatment of Rheumatoid Arthritis to European Medicines Agency
Tickers: GSK, JNJ, SNY, REGN
Occurred on: Sep 12, 2016
Janssen Submits Application to the European Medicines Agency (EMA) to Expand Use of DARZALEX (daratumumab) to Include Combination with Standard of Care Regimens
Ticker: JNJ
Occurred on: Aug 23, 2016
Janssen Submits Application to U.S. FDA to Expand Indication for Daratumumab (DARZALEX)
Ticker: JNJ
Occurred on: Aug 17, 2016
Esketamine Receives Breakthrough Therapy Designation from U.S. Food and Drug Administration for Major Depressive Disorder with Imminent Risk for Suicide
Ticker: JNJ
Occurred on: Aug 16, 2016
Daratumumab (DARZALEX) Granted Breakthrough Therapy Designation by U.S. FDA for Use in Combination with Standard of Care Regimens for Patients with Multiple Myeloma
Ticker: JNJ
Occurred on: Jul 25, 2016
U.S. FDA Approves PREZISTA (darunavir) for Use in Pregnant Women with HIV
Ticker: JNJ
Occurred on: Jul 18, 2016
U.S. FDA Grants Priority Review to Janssen’s New Drug Application for Chewable Mebendazole Tablets Intended to Treat Soil-Transmitted Helminthiasis
Ticker: JNJ
Occurred on: Jul 13, 2016
Simponi Receives European Comission Approval for Treatment of Polyarticular Juvenile Idiopathic Arthritis
Ticker: JNJ
Occurred on: Jun 30, 2016
Ibrutinib (IMBRUVICA) Granted Breakthrough Therapy Designation by U.S. Food and Drug Administration (FDA) for the Development of a Treatment for Chronic Graft-Versus-Host Disease (cGVHD)
Ticker: JNJ
Occurred on: Jun 29, 2016
Newly Published Real-World Evidence Shows Adults with Type 2 Diabetes Significantly Improve Blood Glucose Control and Achieve Treatment Goals When Using INVOKANA canagliflozin
Ticker: JNJ
Occurred on: May 16, 2016
FDA Expands IMBRUVICA Label to Include New Data from Two Key Phase 3 Trials, Adding Overall Survival and Combination Data
Ticker: JNJ
Occurred on: May 09, 2016
Janssen to Unveil New Hepatitis B and C Data at The International Liver Congress
Ticker: JNJ
Occurred on: Apr 14, 2016
Interim Analysis of Phase 3 Trial of Daratumumab Meets Primary Endpoint of Efficacy and Safety in Treating Multiple Myeloma
Ticker: JNJ
Occurred on: Mar 30, 2016
U.S. FDA Approves IMBRUVICA (ibrutinib) for First-line Treatment of Chronic Lymphocytic Leukemia
Tickers: JNJ, ABBV, Janssen Biotech
Occurred on: Mar 04, 2016
FDA Approves Odefsey for Treatment of HIV-1
Tickers: GILD, JNJ
Occurred on: Mar 01, 2016
First Regimen Combining Long Acting Injectable Antiretrovirals; 32-Week LATTE 2 Study Results Presented at CROI
Ticker: JNJ
Occurred on: Feb 23, 2016
FDA’s Arthritis Advisory Committee Recommends Approval of Celltrion’s CT-P13, a Proposed Biosimilar Infliximab, for All Eligible Indications
Tickers: CELLTRION, PFE, MRK, JNJ
Occurred on: Feb 10, 2016
FDA reviewers support Celltrion's biosimilar Remicade, ahead of the Ad Comm meeting on February 9
Tickers: CELLTRION, PFE, JNJ, MRK
Occurred on: Feb 05, 2016
IMBRUVICA (ibrutinib) Phase 2 RESONATE-17 Data Show Robust Clinical Activity and Promising Survival Outcomes in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia with del 17p
Ticker: JNJ
Occurred on: Jan 07, 2016
Janssen has entered into a Definitive Collaboration and License agreement with Bavarian Nordic to Develop Vaccine for Chronic HPV Infections
Tickers: JNJ, BAVA.F
Occurred on: Dec 18, 2015
Janssen's (JNJ) Yondelis for Soft Tissue Sarcomas Approved By FDA
Ticker: JNJ
Occurred on: Oct 23, 2015
Janssen's (JNJ) STELARA Successful in Phase 3 Chrone's Study
Tickers: JNJ, CELG
Occurred on: Oct 19, 2015

Strategic Initiatives (JNJ)

Johnson & Johnson (JNJ) Swiss subsidiary, Janssen, published all-cash public tender offer in Switzerland to acquire all publicly held shares of Actelion.
Tickers: JNJ, ATLNEE.SW
Announcement Date: Mar 31, 2017
JNJ's Ethicon Unit Acquires Private Torax Medical for Undisclosed Sum
Tickers: JNJ, Ethicon, Torax Medical
Announcement Date: Feb 20, 2017
Janssen's (JNJ) Codman Neurosurgery Business Acquired by Integra (IART) for $1.045B in Cash
Tickers: IART, JNJ, Janssen Biotech
Announcement Date: Feb 15, 2017
Akebia Therapeutics (AKBA) Announces Exclusive License Agreement with Janssen Pharma (JNJ) for Portfolio Targeting Hypoxia-Inducible Factors (HIF)
Tickers: AKBA, JNJ
Announcement Date: Feb 13, 2017
Renova Therapeutics Acquires IND Filing for Heart Failure Candidate Stesscopin from Janssen Pharmaceuticals (JNJ) for Undisclosed Amount
Tickers: JNJ, Renova Therapeutics
Announcement Date: Feb 06, 2017
Amgen (AMGN) and Janssen (JNJ) Announce Collaboration Deal to Evaluate Kyprolis and Darzalex in Multiple Myeloma
Tickers: AMGN, JNJ
Announcement Date: Nov 10, 2016
AstraZeneca (AZN) Sells U.S Rights to Rhinocort Aqua OTC Nasal Spray for Allergic and Non-Allergic Rhinitis and Nasal Polyps to Cilag GmbH International (JNJ) for $330MM Cash
Tickers: JNJ, Cilag GmbH International, AZN
Announcement Date: Oct 07, 2016
TRACON (TCON) and Janssen (JNJ) Announce Strategic Licensing Collaboration for TRC253 in Treatment of Prostate Cancer and TRC694 in Treatment of Hematologic Malignancies
Tickers: JNJ, TCON
Announcement Date: Sep 28, 2016
Geron (GERN) Announces $80M License Deal with Janssen (JNJ) to Develop and Commercialize Products Based on GERN's Specialized Oligonucleotide Backbone Chemistry and RNA Interference Candidates for Treatment of Numerous Human Disorders
Tickers: GERN, JNJ
Announcement Date: Sep 19, 2016
Janssen Announces Clinical Collaboration with Bristol-Myers Squibb to Evaluate Immuno-oncology Combination in Lung Cancer
Tickers: JNJ, BMY
Announcement Date: Jul 26, 2016
Johnson & Johnson buys dermocosmetics firm NeoStrata Company
Tickers: JNJ, NeoStrata Company
Announcement Date: Apr 26, 2016
Ethicon Announces Agreement To Acquire NeuWave Medical
Ticker: JNJ
Announcement Date: Mar 07, 2016
Johnson & Johnson Announces Actions To Strengthen Medical Devices Leadership Position In Evolving Healthcare Marketplace
Ticker: JNJ
Announcement Date: Jan 19, 2016
Enterome enters collaboration with Johnson & Johnson Innovation, focused on the discovery of novel targets and therapeutics for Crohn’s disease
Ticker: JNJ
Announcement Date: Jan 07, 2016
Johnson & Johnson Innovation and Janssen Pharmaceuticals, Inc. Announce Agreement with Chia Tai Tianqing Pharmaceutical Group Co., Ltd. to Develop and Commercialize Curative Treatments for Hepatitis B
Ticker: JNJ
Announcement Date: Jan 07, 2016